If it's you then I suggest you get out of the market.
AMBS - Most undervalued small cap bio-tech currently trading under a dime. $30M market cap.
Working with Becton Dickinson to develop LymPro, diagnostic test to detect early stage Alzheimers.
The company's patented drug, MANF, already has three orphan indications.
On "GSS" - Currently trading at .437
Neutral on ABX. Go figure.
Good call. Zacks is neutral here.
Make sense if the company is a potential takeover target.
Consolidation in the gold sector could start at any time with current valuations being so low.